1.1Sulfonyl bridge at X1
The —S(O)₂— bridge joins the two attachment atoms through a tetrahedral sulfur center. Its two oxygens act as hydrogen-bond acceptors and give the bridge a polar surface.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The —S(O)₂— bridge joins the two attachment atoms through a tetrahedral sulfur center. Its two oxygens act as hydrogen-bond acceptors and give the bridge a polar surface.
A single bond to fluorine places a compact substituent at R5. The bond dipole changes the local electrostatic surface at that position.
One ligand carries a cyclodextrin host and the other carries an adamantyl guest. In water, the guest occupies the host cavity and assembles the two ligand modules into a complex that presents both binding groups.
The unit —P(O)(CH₃)— joins the two linker segments through phosphorus–carbon bonds. The tetrahedral phosphorus center sets the local linker geometry, and the phosphoryl oxygen acts as a hydrogen-bond acceptor.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A bivalent degrader links a bromodomain-binding moiety to a ubiquitin ligase recruiter through a covalent spacer. Cultured cells receive the degrader during a defined interval before a transcriptional stimulus. Immunoblotting measures target abundance before and after the stimulus, and a fluorescent transcriptional reporter measures the cellular response.
A thalidomide-derived cereblon ligand replaces the fused-ring recruiter, while the target-binding moiety retains its attachment site. An amide connects a spacer terminating in a carboxyl group to a 4-amino substituent on the ligand's phthalimide ring. The resulting conjugate brings the target protein near the cereblon ubiquitin ligase complex.
A cyanoacrylamide-bearing ligand replaces the target-binding moiety for a protein with an accessible cysteine next to its ligand-binding pocket. The spacer attaches to a separate position on the ligand that faces the solvent, and the recruiter occupies the opposite end of the spacer. The cyanoacrylamide forms a reversible thioether adduct with the target cysteine while the recruiter engages the ubiquitin ligase.
Four conjugates share the same target-binding moiety, ligase recruiter, attachment sites, and terminal amide bonds. Their spacers contain linear segments of 3, 6, 9, or 12 methylene groups between the amides. A concentration series for each conjugate provides measurements of target abundance at 2 and 8 hours.
A split-luciferase complementation assay measures target abundance in cells exposed to the bivalent degrader. A short peptide tag is fused to an endogenous target terminus away from the binding site for the degrader. After exposure, the complementary luciferase fragment and substrate are added, and a plate reader measures luminescence alongside cell viability.
A liquid-handling robot dispenses each conjugate at 10 concentrations into a 384-well plate containing target reporter cells. A plate reader records the target signal and a separate viability signal after incubation. Software normalizes both signals to vehicle controls, fits concentration-response curves, and ranks compounds by maximum target depletion at concentrations that retain at least 80 percent viability.
One R2 site carries —C(O)NH₂, with both nitrogen substituents set to hydrogen. The carbonyl oxygen accepts hydrogen bonds, and the amide NH₂ group donates them.
One R4 site carries —OCH₃, with methyl as R in —OR. The oxygen links the methyl group to the scaffold and acts as a hydrogen-bond acceptor.
R6 is a tetrahydropyran-4-yl group attached through carbon 4. The saturated six-membered ring contains one oxygen and adopts a chair conformation.
One Cy unit is trans-cyclohexane-1,4-diyl, with the two linker segments attached at carbons 1 and 4. In the diequatorial chair conformation, the two segments project outward from opposite ends of the ring.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
L1 is a covalent bond, —NR5—, —O—, —S—, —S(O)—, —S(O)2—, —C(R6)2—, —C(O)—, —C(═S)—, —C(═NR)—, or —C(═N2)—;B · US 2013/0345192 A1 · claim 1
W is CH or N; each of Ra, Rb, Rc, and Rd is independently selected from R, OR, or halogen; each R is independently hydrogen, lower alkyl, or lower haloalkyl;A · US 8,586,600 B2 · ¶ 15
According to another aspect, Y is a 9-10 membered bicyclic, partially unsaturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary bicyclic rings include 2,3-dihydrobenzo[d]isothiazole.A · US 8,586,600 B2 · ¶ 72
Ring A is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;B · US 2013/0345192 A1 · claim 1
In some embodiments, each R2 is independently an optionally substituted group selected from C1-12 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturaB · US 2013/0345192 A1 · ¶ 85
Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with at 1-4 groups independently selected from -Q-Z, oxo, halogen, CN, or C1-6 aliphatic, wherein: Q is a covalent bond or a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocaA · US 8,586,600 B2 · ¶ 47
In some embodiments, L2 is a covalent bond or an optionally substituted, bivalent C1-3 saturated or unsaturated, straight or branched, hydrocarbon chain.B · US 2013/0345192 A1 · ¶ 96
In some embodiments, L2 an optionally substituted, bivalent C1-3 saturated hydrocarbon chain, wherein one methylene u of L2 is optionally replaced by —C(R6)2—, —NR—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, or —SO2—.B · US 2013/0345192 A1 · ¶ 96
One of ordinary skill in the art will recognize that certain reactive functional groups can act as “warheads.” As used herein, the term “warhead” or “warhead group” refers to a functional group present on a compound of the present invention wherein that functional group is capable of covalently binding to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified) present in the binding pocket of certain protein kinases,A · US 8,586,600 B2 · ¶ 43
SiRo3; —(C1-4 straight or branched)alkylene)O—N(Ro)2; or —(C1-4 straight or branched)alkylene)C(O)O—N(Ro)2, wherein each Ro may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, —CH2Ph, —O(CH2)0-1Ph, —CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrencesB · US 2013/0345192 A1 · ¶ 43
An empty cell means only that no passage was reproduced there.
Accordingly, there remains a need to find protein kinase inhibitors useful as therapeutic agents.A · US 8,586,600 B2 · ¶ 6
It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases.A · US 8,586,600 B2 · ¶ 7
Consequently, there is a great need in the art for effective inhibitors for Tec kinases such as Btk.B · US 2013/0345192 A1 · ¶ 3
Accordingly, provided compounds can be used in a variety of methods including in vitro screening and activity assays as well as in vivo pre-clinical, clinical, and therapeutic settings, as described in detail herein.B · US 2013/0345192 A1 · ¶
patent.fyi, US 2026/0356847 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356847/, SHA-256 8f9e9b06e47afc0f6e801693aa9deb0ec057ab291040349b293c1d718fc2a840